Please assess the completion status of the following clinical trial:

Trial Title: Valganciclovir to Reduce T Cell Activation in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HIV \>1 year in duration.~* Age \>18~* Cytomegalovirus (CMV) antibody positive.~* All Cluster of Differentiation 4 (CD4)+ T cell counts in the last year and at screening \<350 cells/mm3~* On a stable highly addictive antiretroviral therapy (HAART) regimen (DHHS definition) for the preceding 6 months.~  * 90% adherence to antiretroviral therapy within the preceding 30 days.~* Females of childbearing potential must have a negative serum pregnancy test at screening and all subjects must agree to use a double-barrier method of contraception throughout the study period.~* Screening %Cluster of differentiation 38 (CD38)+ Human leukocyte antigen-D-related (HLA-DR)+ Cluster of differentiation 8 (CD8)+ T cells \>10%~Exclusion Criteria:~* Patients intending to modify antiretroviral therapy in the next 16 weeks.~* Serious illness requiring hospitalization or parental antibiotics within preceding 3 months.~* Evidence of active symptomatic CMV end-organ disease.~* Treatment with valganciclovir or ganciclovir in the past 30 days.~* Concurrent treatment with immunomodulatory drugs.~* Concurrent treatment with nephrotoxic drugs~* Screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<100,000 cells/mm3, hemoglobin \< 8mg/dL, estimated creatinine clearance \<50 mL/minute.~* Men who are considering having children will also be excluded given potential effects of valganciclovir on spermatogenesis.~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): 900mg PO qd
- Placebo (Type: PLACEBO_COMPARATOR): 900mg PO qd

Based on this trial design, predict the completion outcome and termination type (if applicable).